top of page

Our Team

  • Xun Meng, Ph.D. – Chief Executive Officer

Dr. Meng is a serial entrepreneur and has successfully launched 4 biotechnology companies in a 12-year span, among which Epitome Biosystems was acquired by Millipore.  He founded Abmart where he established the MabArray and HMP-MabArray antibody/target discovery platform. Dr. Meng has an extensive technical background and has broad expertise in various types of omics, nanotechnology, high-throughput biomarkers, discovery methods of diagnostic and therapeutic targets, and has filed many patents.  He is also a distinguished adjunct professor of Xibei University in China. 

  • Shu-Hui Liu, Ph.D. – Chief Scientific Officer

Dr. Liu has over 20 years of biotech/pharmaceutical industry experience focusing on developing biologics-based oncology drugs. She specializes in antibody, ADC, bi-specific molecule and CAR T cell therapeutics, with experience in both preclinical research and clinical development. Prior to joining Multitude Therapeutics, she was the director of the Tumor Biology group at Pfizer in South San Francisco, California.  Prior to that she worked at biotech companies on various cancer target discovery projects. She has brought a number of discovery programs to the clinic and is the author/coauthor of multiple publications and numerous patents.

  • Yanfang Tang – Chief Operating Officer 

Ms. Tang has nearly 20 years of biotechnology operation experience. She started working in the antibody engineering field and later became Multitude's operation, BD, and management leader. She has led several rounds of financing since the establishment of the company and successfully completed multiple BD transactions. 

Yanfang Picture.jpg
  • Xiaona Jing, Ph.D. – SVP Global Product Development & Partnering

Dr. Jing joined Multitude with extensive international biopharmaceutical development experience from preclinical to the commercial stage in both large pharma and small biotech including Roche, Genmab and NBE-Therapeutics. She supported the development of Genmab´s first approved ADC Tivdak™ and was a key contributor to the transition of the Swiss ADC biotech NBE-Therapeutics into the clinical stage and thereafter successful acquisition by BI.  

Xiaona Jing (002).jpg
bottom of page